Three trends currently helping companies expand their portfolios.
Sterile suspensions are particularly difficult to manufacture. This technical article covers factors for success, including particle size, vehicle formulation, and considerations for high-shear mixing.
Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies.
When developing a parenteral product, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. With careful planning and strategic foresight, these advantages can be leveraged to great effect during the development program. Read the whitepaper to learn more.
A third-party study was conducted to compare the performance of Thermo Scientific™ Nunc™ Roller Bottles (1.2 and 2.5X) and 850 cm2 roller bottles from another supplier, for the culturing of ST, Vero, and MDBK cells.
A rapid, flexible, and high-yield approach both hybridoma expansion and for antibody production using a serum-free medium in Nunc PETG Roller Bottles.
OptiForm® Solution Suite is a comprehensive offering which incorporates everything you need to progress your candidate from late-stage discovery to phase I.
A platform that combines drug development expertise and biomanufacturing and integrated services to offer advantages to ADC developers.
This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.
The path through drug development is marked by detours, roadblocks and very few shortcuts. At times you may feel that you’re the only person keeping your molecule on its critical path. Unexpected delays can lead to missed milestones, rework and delayed timelines – all setbacks that no one wants to explain to their investors.
With Patheon OneSource™ you can combine your drug substance and drug product development and manufacturing into a single customized solution to simplify your supply chain and accelerate your discovery to proof of concept.
To be successful, new treatments require superior real world outcomes providing market differentiation and delivering the best outcomes to you, your stakeholders, and most importantly the patients who depend on your therapy.
